A deletion - optimization strategy based on an initial heptapeptide le
ad structure 1 led to potent and selective neurokinin NK2 antagonists
5 (pK(B)=9.3) and 9 (pK(B)=7.9) of substantially reduced molecular siz
e. Tetrapeptide 5 (0.1 mumol/Kg i.v.) potently inhibits NK2 agonist-in
duced bronchoconstriction in guinea-pigs. Whilst less potent than 5 in
vivo, the dipeptoid 9 (5 mumol/Kg i.v.) had a significantly longer bi
ological half-life (> 2 h), and provides a potential lead towards non-
peptide analogues.